[1]
Reich, K., Papp, K., Blauvelt, A., Langley, R., Armstrong, A., Warren, R., Gordon, K., Merola, J., Madden, C., Wang, M., Vanvoorden, V. and Lebwohl, M. 2020. Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s82. DOI:https://doi.org/10.25251/skin.4.supp.82.